Prognostic significance of Ki67 during neoadjuvant chemotherapy in primary unresectable ovarian cancer

Kaya, Ryusuke; Takanashi, Hiroko; Nakajima, Akari; Saito, Ryosuke; Yamaguchi, Noriko; Morimoto, Keiji; Isonishi, Seiji

doi:10.1111/jog.14981

Cited by 4 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, the variations in the study population could also be a limitation. Some studies included patients with stage I to IV ovarian cancer [12,14], whereas only patients with advanced ovarian cancer were included in some other studies [17,18]. Meanwhile, the included pathological types also differed.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of Ki-67 in patients with ovarian cancer

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

This study aimed to investigate the prognostic value of Ki-67 antigen (Ki-67) in patients with epithelial ovarian cancer. A retrospective review identified a cohort of 78 patients with epithelial ovarian cancer. The association between Ki-67 expression and clinicopathological characteristics and survival was analyzed. High Ki-67 expression was significantly associated with high stage, high histological grade, ascites, and high level of cancer antigen 125 (CA125) (p = 0.011, p = 0.031, p = 0.033, p = 0.004, respectively). In addition, high Ki-67 expression was significantly associated with poor prognosis (p = 0.002), which was further confirmed using a multivariate Cox regression hazards model (Hazard Ratio (HR) = 1.797, 95% confidence interval (CI) = 1.038–3.111, p = 0.026). In conclusion, Ki-67 expression may be a significant prognostic factor in epithelial ovarian cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of Ki-67 in patients with ovarian cancer

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

show abstract

“…Recent studies have discovered that Ki67 can be used as a diagnostic and prognostic biomarker in renal cancer ( 6 ), breast cancer ( 20 , 22 ), ovarian cancer ( 23 ), craniopharyngioma ( 24 ) and neuroendocrine neoplasms ( 25 ). However, the prognostic role of Ki67 in prostate cancer remains ambiguous and has not been thoroughly explored.…”

Section: Discussionmentioning

confidence: 99%

Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy

Che

et al. 2023

Front. Surg.

View full text Add to dashboard Cite

BackgroundProstate-specific antigen (PSA) is a critical part of prostate cancer (PCa) screening, diagnosis, staging, and prognosis. However, elevated PSA levels can also be caused by several external factors. To improve the specificity and sensitivity of PSA in clinical practice, we explored whether markers or parameters may be used as prognostic targets for PCa by long-term follow-up.MethodsA total of 121 PCa patients who underwent laparoscopic radical prostatectomy (LRP) were included in our study, all of whom underwent imaging and preoperative pathological diagnosis. Endocrine therapy has long been applied to treat postoperative patients. The prognosis of enrolled patients was followed, and statistics were collected. Spearman's correlation analysis was applied to examine the relationship and clinical parameters. Kaplan–Meier analysis was used to process the clinical variables of PCa patients. Cox proportional hazards regression analysis was applied to examine univariate and multivariate variables.ResultsThe Gleason score (GS), PSA, clinical stage, nerve infiltration, organ confinement, Ki67 and apparent diffusion coefficient (ADC) were significantly associated with prognosis (all P < 0.05). The GS, PSA, clinical stage, organ confined, Ki67, nerve infiltration and ADC were included in the multivariate analysis (all P < 0.05). Ultimately, Ki67 and the ADC were found to provide meaningful predictive information (both P < 0.05).ConclusionsKi67 and the ADC may be clinically and analytically valid prognostic biomarkers and imaging parameters in PCa. They may be useful for predicting the prognosis and risk of PCa patients undergoing postoperative routine endocrine therapy.

show abstract